AstraZeneca writes off its second pivotal COPD trial for Fasenra, killing expansion plans
You can write off any upside AstraZeneca’s respiratory drug Fasenra (benralizumab) may have had left on COPD.
The drug, approved last fall for a severe …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
